NEW YORK, July 18 (Praxis Press) A new class of nonsteroidal anti-inflammatory drugs selectively inhibits cyclooxygenase (COX)-2 and may produce fewer adverse effects than nonselective inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback